Core Viewpoint - Heng Rui Medicine (01276) has received approval from the National Medical Products Administration for the clinical trial of HRS-5041, a new selective AR-PROTAC small molecule aimed at treating prostate cancer [1] Company Summary - HRS-5041 is designed to effectively degrade androgen receptor (AR) proteins, including various mutant forms, showing significant potential to overcome resistance compared to second-generation AR inhibitors [1] - The total research and development investment for the HRS-5041 project has reached approximately 69.19 million yuan [1] Industry Summary - Currently, there are no similar products approved for market release domestically or internationally, indicating a unique position for HRS-5041 in the prostate cancer treatment landscape [1]